| scholarly article | Q13442814 |
| P50 | author | Tadao Akizawa | Q92774606 |
| Eduardo Slatopolsky | Q112554375 | ||
| Takashi Akiba | Q126120186 | ||
| P2093 | author name string | Masashi Suzuki | |
| Etsuro Ogata | |||
| Yasuo Ohashi | |||
| Kiyoshi Kurokawa | |||
| Yoshiki Nishizawa | |||
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | hyperparathyroidism | Q1344835 |
| secondary hyperparathyroidism | Q3622611 | ||
| P304 | page(s) | 28-36 | |
| P577 | publication date | 2002-01-01 | |
| P1433 | published in | Nephrology Dialysis Transplantation | Q15710302 |
| P1476 | title | Long-term effect of 1,25-dihydroxy-22-oxavitamin D(3) on secondary hyperparathyroidism in haemodialysis patients. One-year administration study | |
| P478 | volume | 17 Suppl 10 |
| Q37310824 | Calcimimetics or vitamin D analogs for suppressing parathyroid hormone in end-stage renal disease: time for a paradigm shift? |
| Q36947391 | Cinacalcet HCl and concurrent low-dose vitamin D improves treatment of secondary hyperparathyroidism in dialysis patients compared with vitamin D alone: the ACHIEVE study results |
| Q37912038 | Diseases of the parathyroid gland in chronic kidney disease. |
| Q38775426 | Management of secondary hyperparathyroidism: how and why? |
| Q36947028 | Nonclassical aspects of differential vitamin D receptor activation: implications for survival in patients with chronic kidney disease |
| Q46568744 | Pretreatment plasma intact parathyroid hormone and serum calcium levels, but not serum phosphate levels, predict the response to maxacalcitol therapy in dialysis patients with secondary hyperparathyroidism |
| Q50101289 | The Use of Vitamin D Metabolites and Analogues in the Treatment of Chronic Kidney Disease |
| Q35026640 | Treatment of secondary hyperparathyroidism in kidney disease: what we know and do not know about use of calcimimetics and vitamin D analogs |
Search more.